{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:55:41Z","timestamp":1790625341567,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01299-8","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:18:11Z","timestamp":1788977891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Verification of a Physiologically-based Pharmacokinetic Model for Predicting CYP3A4-mediated Simvastatin and Simvastatin Acid Drug-drug Interactions"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2016-9930","authenticated-orcid":false,"given":"Bridget L.","family":"Morse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4084-2729","authenticated-orcid":false,"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2269-9193","authenticated-orcid":false,"given":"Jeffrey J.","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4645-0763","authenticated-orcid":false,"given":"Maria M.","family":"Posada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1808-6881","authenticated-orcid":false,"given":"Gemma L.","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0268-309X","authenticated-orcid":false,"given":"Stephen D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"1299_CR1","unstructured":"Kane SP. ClinCalc DrugStats database, version 2025.08. 2025. Available from: ClinCalc: https:\/\/clincalc.com\/DrugStats. Accessed 1 Mar 2026."},{"key":"1299_CR2","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","volume":"94","author":"TA Jacobson","year":"2004","unstructured":"Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94:1140\u20136.","journal-title":"Am J Cardiol"},{"key":"1299_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.clpt.2005.11.016","volume":"79","author":"E Chung","year":"2006","unstructured":"Chung E, Nafziger AN, Kazierad DJ, Bertino JS Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther. 2006;79:350\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0009-9236(98)90165-5","volume":"63","author":"PJ Neuvonen","year":"1998","unstructured":"Neuvonen PJ, Kantola T, Kivist\u00f6 KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63:332\u201341.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1067\/mcp.2000.110216","volume":"68","author":"JJ Lilja","year":"2000","unstructured":"Lilja JJ, Kivist\u00f6 KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther. 2000;68:384\u201390.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0009-9236(98)90130-8","volume":"64","author":"JJ Lilja","year":"1998","unstructured":"Lilja JJ, Kivist\u00f6 KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther. 1998;64:477\u201383.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0009-9236(95)90048-9","volume":"58","author":"U Fuhr","year":"1995","unstructured":"Fuhr U, Kummert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions? Clin Pharmacol Ther. 1995;58:365\u201373.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1177\/0091270003256059","volume":"43","author":"ML Veronese","year":"2003","unstructured":"Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E, et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol. 2003;43:831\u20139.","journal-title":"J Clin Pharmacol"},{"key":"1299_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","volume":"16","author":"MK Pasanen","year":"2006","unstructured":"Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006;16:873\u20139.","journal-title":"Pharmacogenet Genomics"},{"key":"1299_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0009-9236(98)90151-5","volume":"64","author":"T Kantola","year":"1998","unstructured":"Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998;64:177\u201382.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR11","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1067\/mcp.2000.111414","volume":"68","author":"C Kyrklund","year":"2000","unstructured":"Kyrklund C, Backman JT, Kivist\u00f6 KT, Neuvonen M, Laitila J, Neuvonen PJ. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 2000;68:592\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1248\/bpb.b14-00679","volume":"38","author":"X Wang","year":"2015","unstructured":"Wang X, Zhu HJ, Markowitz JS. Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin. Biol Pharm Bull. 2015;38:292\u20137.","journal-title":"Biol Pharm Bull"},{"key":"1299_CR13","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1023\/A:1018923325359","volume":"10","author":"AS Kearney","year":"1993","unstructured":"Kearney AS, Crawford LF, Mehta SC, Radebaugh GW. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res. 1993;10:1461\u20135.","journal-title":"Pharm Res"},{"key":"1299_CR14","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/psp4.12447","volume":"8","author":"BL Morse","year":"2019","unstructured":"Morse BL, Alberts JJ, Posada MM, Rehmel J, Kolur A, Tham LS, et al. Physiologically-based pharmacokinetic modeling of atorvastatin incorporating delayed gastric emptying and acid-to-lactone conversion. CPT Pharmacomet Syst Pharmacol. 2019;8:664\u201375.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1299_CR15","unstructured":"Food and Drug Administration. Clinical pharmacology review: simvastatin suspension. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/206679Orig1s000ClinPharmR.pdf. Accessed 27 Apr 2020."},{"key":"1299_CR16","unstructured":"Food and Drug Administration. Clinical pharmacology review: juvisync. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202343Orig1s000TOC.html. Accessed 15 Jun 2022."},{"key":"1299_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1046\/j.1365-2125.2002.01633.x","volume":"54","author":"T Kosoglou","year":"2002","unstructured":"Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol. 2002;54:309\u201319.","journal-title":"Br J Clin Pharmacol"},{"key":"1299_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1067\/mcp.2000.104609","volume":"67","author":"O Mousa","year":"2000","unstructured":"Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000;67:267\u201374.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR19","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s11095-007-9519-6","volume":"25","author":"M Tubic-Grozdanis","year":"2008","unstructured":"Tubic-Grozdanis M, Hilfinger JM, Amidon GL, Kim JS, Kijek P, Staubach P, et al. Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm Res. 2008;25:1591\u2013600.","journal-title":"Pharm Res"},{"key":"1299_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1067\/mcp.2000.108507","volume":"68","author":"JT Backman","year":"2000","unstructured":"Backman JT, Kyrklund C, Kivist\u00f6 KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 2000;68:122\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00228-014-1801-z","volume":"71","author":"BK Birmingham","year":"2015","unstructured":"Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Wei C, Chen Y, et al. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur J Clin Pharmacol. 2015;71:341\u201355.","journal-title":"Eur J Clin Pharmacol"},{"key":"1299_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/clpt.2009.79","volume":"86","author":"JE Keskitalo","year":"2009","unstructured":"Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86:197\u2013203.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/0091270008326718","volume":"49","author":"R Krishna","year":"2009","unstructured":"Krishna R, Bergman AJ, Jin B, Garg A, Roadcap B, Chiou R, et al. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers. J Clin Pharmacol. 2009;49:80\u20137.","journal-title":"J Clin Pharmacol"},{"key":"1299_CR24","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","volume":"80","author":"M Niemi","year":"2006","unstructured":"Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006;80:356\u201366.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40268-013-0016-6","volume":"13","author":"A Falc\u00e3o","year":"2013","unstructured":"Falc\u00e3o A, Lima R, Sousa R, Nunes T, Soares-da-Silva P. Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects. Drugs R D. 2013;13:137\u201343.","journal-title":"Drugs R D"},{"key":"1299_CR26","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00228-003-0700-5","volume":"59","author":"M Ucar","year":"2004","unstructured":"Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, Mj\u00f6rndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol. 2004;59:879\u201382.","journal-title":"Eur J Clin Pharmacol"},{"key":"1299_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/cpdd.27","volume":"2","author":"S Teng","year":"2013","unstructured":"Teng S, Potvin D, Mamputu JC, Vincent G, Zoltowska M, Morin J, et al. Impact of tesamorelin, a growth hormone-releasing factor (GRF) analogue, on the pharmacokinetics of simvastatin and ritonavir in healthy volunteers. Clin Pharmacol Drug Dev. 2013;2:237\u201345.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1299_CR28","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1185\/030079907X233296","volume":"23","author":"SP Ayalasomayajula","year":"2007","unstructured":"Ayalasomayajula SP, Dole K, He YL, Ligueros-Saylan M, Wang Y, Campestrini J, et al. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin. 2007;23:2913\u201320.","journal-title":"Curr Med Res Opin"},{"key":"1299_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0091270008330983","volume":"49","author":"AJ Bergman","year":"2009","unstructured":"Bergman AJ, Cote J, Maes A, Zhao JJ, Roadcap BA, Sun L, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol. 2009;49:483\u20138.","journal-title":"J Clin Pharmacol"},{"key":"1299_CR30","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00228-014-1674-1","volume":"70","author":"J Dingemanse","year":"2014","unstructured":"Dingemanse J, Nicolas LB, van Bortel L. Investigation of combined CYP3A4 inductive\/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882. Eur J Clin Pharmacol. 2014;70:675\u201384.","journal-title":"Eur J Clin Pharmacol"},{"key":"1299_CR31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/cpdd.1076","volume":"11","author":"D Groenendaal-van de Meent","year":"2022","unstructured":"Groenendaal-van de Meent D, den Adel M, Kerbusch V, van Dijk J, Shibata T, Kato K, et al. Effect of roxadustat on the pharmacokinetics of simvastatin, rosuvastatin, and atorvastatin in healthy subjects: results from 3 phase 1, open-label, 1-sequence, crossover studies. Clin Pharmacol Drug Dev. 2022;11:486\u2013501.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1299_CR32","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/0091270004273992","volume":"45","author":"M Jerling","year":"2005","unstructured":"Jerling M, Huan BL, Leung K, Chu N, Abdallah H, Hussein Z. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45:422\u201333.","journal-title":"J Clin Pharmacol"},{"key":"1299_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/cpt.1599","volume":"107","author":"NS Jones","year":"2020","unstructured":"Jones NS, Yoshida K, Salphati L, Kenny JR, Durk MR, Chinn LW. Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI. Clin Pharmacol Ther. 2020;107:269\u201377.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101809","volume":"57","author":"B Poller","year":"2019","unstructured":"Poller B, Woessner R, Barve A, Tillmann HC, Vemula J, Nica A, et al. Fevipiprant has a low risk of influencing co-medication pharmacokinetics: impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes. Pulm Pharmacol Ther. 2019;57:101809.","journal-title":"Pulm Pharmacol Ther"},{"key":"1299_CR35","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1124\/dmd.109.026658","volume":"37","author":"X Zhang","year":"2009","unstructured":"Zhang X, Quinney SK, Gorski JC, Jones DR, Hall SD. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos. 2009;37:1587\u201397.","journal-title":"Drug Metab Dispos"},{"key":"1299_CR36","first-page":"511","volume":"82","author":"KT Olkkola","year":"1996","unstructured":"Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996;82:511\u20136.","journal-title":"Anesth Analg"},{"key":"1299_CR37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/clpt.1993.25","volume":"53","author":"KT Olkkola","year":"1993","unstructured":"Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993;53:298\u2013305.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1124\/dmd.109.028746","volume":"38","author":"SK Quinney","year":"2010","unstructured":"Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, Hall SD. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos. 2010;38:241\u20138.","journal-title":"Drug Metab Dispos"},{"key":"1299_CR39","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1124\/dmd.105.008730","volume":"34","author":"JY Chien","year":"2006","unstructured":"Chien JY, Lucksiri A, Ernest CS 2nd, Gorski JC, Wrighton SA, Hall SD. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos. 2006;34:1208\u201319.","journal-title":"Drug Metab Dispos"},{"key":"1299_CR40","unstructured":"Han B, Dickinson GL, Turner PK, Hall SD. Prediction\u00a0of CYP3A mediated drug-drug interactions: estimation of gut wall and hepatic contributions. Poster presented at:\u00a0American Society for Clinical Pharmacology and Therapeutics Annual Meeting; Indianapolis, IN, March 5\u20139. 2013."},{"key":"1299_CR41","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1124\/dmd.107.018663","volume":"36","author":"OA Fahmi","year":"2008","unstructured":"Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, Nettleton D. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos. 2008;36:1698\u2013708.","journal-title":"Drug Metab Dispos"},{"key":"1299_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1124\/dmd.32.2.259","volume":"32","author":"YH Wang","year":"2004","unstructured":"Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004;32:259\u201366.","journal-title":"Drug Metab Dispos"},{"key":"1299_CR43","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/j.1365-2125.2007.03070.x","volume":"65","author":"KA Youdim","year":"2008","unstructured":"Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, Darekar A, et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol. 2008;65:680\u201392.","journal-title":"Br J Clin Pharmacol"},{"key":"1299_CR44","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijpharm.2016.06.048","volume":"510","author":"S Geboers","year":"2016","unstructured":"Geboers S, Stappaerts J, Tack J, Annaert P, Augustijns P. In vitro and in vivo investigation of the gastrointestinal behavior of simvastatin. Int J Pharm. 2016;510:296\u2013303.","journal-title":"Int J Pharm"},{"key":"1299_CR45","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1007\/s11095-014-1581-2","volume":"32","author":"N Tsamandouras","year":"2015","unstructured":"Tsamandouras N, Dickinson G, Guo Y, Hall S, Rostami-Hodjegan A, Galetin A, et al. Development and application of a mechanistic pharmacokinetic model for simvastatin and its active metabolite simvastatin acid using an integrated population PBPK approach. Pharm Res. 2015;32:1864\u201383.","journal-title":"Pharm Res"},{"key":"1299_CR46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.eplepsyres.2013.04.009","volume":"106","author":"A Falcao","year":"2013","unstructured":"Falcao A, Pinto R, Nunes T, Soares-da-Silva P. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. Epilepsy Res. 2013;106:244\u20139.","journal-title":"Epilepsy Res"},{"key":"1299_CR47","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/clpt.2014.55","volume":"96","author":"N Tsamandouras","year":"2014","unstructured":"Tsamandouras N, Dickinson G, Guo Y, Hall S, Rostami-Hodjegan A, Galetin A, et al. Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach. Clin Pharmacol Ther. 2014;96:90\u2013100.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR48","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/FPC.0000000000000176","volume":"25","author":"HY Choi","year":"2015","unstructured":"Choi HY, Bae KS, Cho SH, Ghim JL, Choe S, Jung JA, et al. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid. Pharmacogenet Genomics. 2015;25:595\u2013608.","journal-title":"Pharmacogenet Genomics"},{"key":"1299_CR49","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/cpt.1596","volume":"107","author":"Y Guo","year":"2020","unstructured":"Guo Y, Lucksiri A, Dickinson GL, Vuppalanchi RK, Hilligoss JK, Hall SD. Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions. Clin Pharmacol Ther. 2020;107:246\u201356.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR50","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/cpt.525","volume":"101","author":"T Prueksaritanont","year":"2017","unstructured":"Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, et al. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 2017;101:519\u201330.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR51","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1124\/dmd.114.058404","volume":"42","author":"AS Darwich","year":"2014","unstructured":"Darwich AS, Aslam U, Ashcroft DM, Rostami-Hodjegan A. Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans. Drug Metab Dispos. 2014;42:2016\u201322.","journal-title":"Drug Metab Dispos"},{"key":"1299_CR52","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1124\/dmd.110.036103","volume":"39","author":"EJ Guest","year":"2011","unstructured":"Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos. 2011;39:170\u20133.","journal-title":"Drug Metab Dispos"},{"key":"1299_CR53","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2165\/00003088-200746080-00005","volume":"46","author":"Y Ohno","year":"2007","unstructured":"Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007;46:681\u201396.","journal-title":"Clin Pharmacokinet"},{"key":"1299_CR54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2165\/11592620-000000000-00000","volume":"50","author":"M Tod","year":"2011","unstructured":"Tod M, Goutelle S, Clavel-Grabit F, Nicolas G, Charpiat B. Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions. Clin Pharmacokinet. 2011;50:519\u201330.","journal-title":"Clin Pharmacokinet"},{"key":"1299_CR55","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/cpt.2887","volume":"113","author":"E Jarvinen","year":"2023","unstructured":"Jarvinen E, Hammer HS, Potz O, Ingelman-Sundberg M, Stage TB. 3D Spheroid Primary Human Hepatocytes for Prediction of Cytochrome P450 and Drug Transporter Induction. Clin Pharmacol Ther. 2023;113:1284\u201394.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1124\/jpet.120.000139","volume":"375","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Chen C, Chen SJ, Chen XQ, Shuster DJ, Puszczalo PD, et al. Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression. J Pharmacol Exp Ther. 2020;375:139\u201351.","journal-title":"J Pharmacol Exp Ther"},{"key":"1299_CR57","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1124\/dmd.119.089615","volume":"48","author":"AD Rodrigues","year":"2020","unstructured":"Rodrigues AD, Lai Y, Shen H, Varma MVS, Rowland A, Oswald S. Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions? Drug Metab Dispos. 2020;48:205\u201316.","journal-title":"Drug Metab Dispos"},{"key":"1299_CR58","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/cpt.3414","volume":"117","author":"A Gessner","year":"2025","unstructured":"Gessner A, Konig J, Wenisch P, Heinrich MR, Stopfer P, Fromm MF, et al. New Biomarkers for Renal Transporter-Mediated Drug-Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans. Clin Pharmacol Ther. 2025;117:130\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR59","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1046\/j.1365-2125.2003.01720.x","volume":"55","author":"KJ Cooper","year":"2003","unstructured":"Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol. 2003;55:94\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"1299_CR60","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1124\/dmd.118.081125","volume":"46","author":"H Shen","year":"2018","unstructured":"Shen H, Christopher L, Lai Y, Gong J, Kandoussi H, Garonzik S, et al. Further studies to support the use of coproporphyrin I and III as novel clinical biomarkers for evaluating the potential for organic anion transporting polypeptide 1B1 and OATP1B3 inhibition. Drug Metab Dispos. 2018;46:1075\u201382.","journal-title":"Drug Metab Dispos"},{"key":"1299_CR61","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/jmri.22458","volume":"33","author":"A Huppertz","year":"2011","unstructured":"Huppertz A, Breuer J, Fels LM, Schultze-Mosgau M, Sutter G, Klein S, et al. Evaluation of possible drug-drug interaction between gadoxetic acid and erythromycin as an inhibitor of organic anion transporting peptides (OATP). J Magn Reson Imaging. 2011;33:409\u201316.","journal-title":"J Magn Reson Imaging"},{"key":"1299_CR62","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00228-003-0573-7","volume":"59","author":"KJ Cooper","year":"2003","unstructured":"Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2003;59:51\u20136.","journal-title":"Eur J Clin Pharmacol"},{"key":"1299_CR63","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s002280050408","volume":"53","author":"W Muck","year":"1998","unstructured":"Muck W, Ochmann K, Rohde G, Unger S, Kuhlmann J. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol. 1998;53:469\u201373.","journal-title":"Eur J Clin Pharmacol"},{"key":"1299_CR64","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/009127009903900510","volume":"39","author":"PH Siedlik","year":"1999","unstructured":"Siedlik PH, Olson SC, Yang BB, Stern RH. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol. 1999;39:501\u20134.","journal-title":"J Clin Pharmacol"},{"key":"1299_CR65","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1124\/dmd.106.013268","volume":"35","author":"P Li","year":"2007","unstructured":"Li P, Callery PS, Gan LS, Balani SK. Esterase inhibition attribute of grapefruit juice leading to a new drug interaction. Drug Metab Dispos. 2007;35:1023\u201331.","journal-title":"Drug Metab Dispos"},{"key":"1299_CR66","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0090-9556(25)07595-6","volume":"18","author":"S Vickers","year":"1990","unstructured":"Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos. 1990;18:138\u201345.","journal-title":"Drug Metab Dispos"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01299-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01299-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01299-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:02:53Z","timestamp":1790622173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01299-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":66,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01299-8","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"142"}}